scholarly journals The Biased Ligands NGF and NT-3 Differentially Stabilize Trk-A Dimers

2021 ◽  
Vol 120 (1) ◽  
pp. 55-63
Author(s):  
Fozia Ahmed ◽  
Elmer Zapata-Mercado ◽  
Sanim Rahman ◽  
Kalina Hristova
Keyword(s):  
1999 ◽  
Vol 15 (1) ◽  
pp. 84-87
Author(s):  
Débora Marques de Miranda ◽  
Marco Aurélio Romano Silva ◽  
Antônio Lúcio Teixeira
Keyword(s):  

A Síndrome de Gilles de la Tourette (ST) é uma entidade neuropsiquiátrica caracterizada pela presença de tics e com importante componente hereditário. Muitos grupos vem estudando os aspectos genéticos da ST, mas frequentemente os achados não se sustentam em estudos subsequentes e fica clara toda a dificuldade em estabelecer os genes relacionados com a ST. Entretanto, no último ano foi publicado estudo que correlaciona mutação no gene da Slit and Trk-like family member 1 (SLITRK1) com a presença ST em um pequeno grupo de pacientes. Esse gene codifica a proteína SLITRK1 que é homóloga às proteínas SLIT e o receptor de tirosina cinase (TRK). A família das proteínas SLIT estão envolvidos no direcionamento axonal durante o cruzamento da linha média na medula vertebral. Enquanto o receptor de TRK acelera a diferenciação induzida pelo fator de crescimento neuronal. A SLITRK aparentemente está envolvida no crescimento de dendritos e axônios. Faltam estudos que avaliem a presença de mutações no gene da SLITRK1 em outras populações, assim como que avaliem a possibilidade de alteração de outros genes dessa via de sinalização. Entretanto, caso se confirmem as alterações no gene da SLITRK1, ou de genes correlacionados, o entendimento e o estudo de ST passará a envolver o direcionamento axonal e especialmente as proteínas da via SLITRK-SLIT-ROBO.


1997 ◽  
Vol 6 (1) ◽  
pp. 10-16 ◽  
Author(s):  
Enrique Nogueira ◽  
Samuel Navarro ◽  
Antonio Pellín ◽  
Antonio Llombart-Bosch

1994 ◽  
Vol 14 (1) ◽  
pp. 759-767
Author(s):  
A Nakagawara ◽  
C G Azar ◽  
N J Scavarda ◽  
G M Brodeur

There is considerable interest in the role of the TRK family of neuotrophin receptors in regulating growth and differentiation in normal and neoplastic nerve cells. A neuroblastoma is a common pediatric tumor derived from the neural crest, and the majority of favorable neuroblastomas express a high level of TRK-A mRNA. However, little is known about the expression or function of TRK-B in these tumors. TRK-B encodes a tyrosine kinase that binds to brain-derived neuotrophic factor (BDNF), as well as neurotrophin-3 (NT-3) and NT-4/5. We have studied the N-myc-amplified human neuroblastoma cell line, SMS-KCN, which expresses both TRK-B and BDNF. Exogenous BDNF induces tyrosine phosphorylation of TRK-B as well as phosphorylation of phospholipase C-gamma 1, the extracellular signal-regulated kinases 1 and 2, and phosphatidylinositol-3 kinase. BDNF also induces expression of the immediate-early genes c-FOS and NGFI-A but not NGFI-B or NGFI-C. In addition, BDNF appears to promote cell survival and neurite outgrowth. SMS-KCN cells also express TRK-A, which is phosphorylated in response to nerve growth factor. However, the downstream TRK-A signaling is apparently defective. Finally, we determined that in a series of 74 primary neuroblastomas, 36% express TRK-B mRNA, 68% express BDNF mRNA, and 31% express both. Truncated TRK-B appears to be preferentially expressed in more-differentiated tumors (ganglioneuromas and ganglioneuroblastomas), whereas full-length TRK-B is expressed almost exclusively in immature neuroblastomas with N-myc amplification. Our findings suggest that in TRK-B-expressing human neuroblastomas, BDNF promotes survival and induces neurite outgrowth in an autocrine or paracrine manner. The BDNF/TRK-B pathway may be particularly important for growth and differentiation of neuroblastomas with N-myc amplification.


2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e15725-e15725
Author(s):  
Shengjun Ji

e15725 Background: Pancreatic cancer is an uncommon but fatal malignant tumor, only 20% of which show any significant response to chemo-radiotherapy. Tumor metabolism research revealed that pancreatic cancer cells highly dependent on cholesterol uptake. So, in the present study, we have determined the effectiveness of atorvastatin, one drug originally used to lower cholesterol, against pancreatic carcinogenesis in various pancreatic cancer cell lines. Methods: To investigate atorvastatin effects in pancreatic cancer cells, two cell lines (PANC-1 and SW1990) were treated with different atorvastatin doses. The anti-proliferative, apoptotic and anti-invasive properties of atorvastatin were evaluated using MTS, cytoplasmic histone-DNA fragmentation and matrigel invasive assays, respectively. And western blot was used to evaluate the neurotrophin receptor signaling of NGF/Trk A, BDNF/TrkB and NT3/Trk C. Results: Atorvastatin suppressed pancreatic cancer cells proliferation, clone formation and invasion in a dose-dependent manner. The dose of atorvastatin at 10^-5mmol/L would be able to achieve obvious anti-tumor effect in vitro. Cell-cycle analysis demonstrated that cells were arrested in the S phase. Western blot showed increased protein expression of cleaved caspase-3, caspase-9, p21, p-chk2 and decrease in protein level of NGF/Trk A and NT3/Trk C. Conclusions: The current results demonstrated the anti-tumor effects of atorvastatin on pancreatic cancer cells, providing initial evidence towards its potential therapeutic use. Acknowledgment:This study was supported by Suzhou Cancer Clinical Medical Center Szzx201506.


Sign in / Sign up

Export Citation Format

Share Document